Background The aim of the study was to calculate the cost to the UK National Health Service of providing treatment services for patients with sickle cell disorders. The rates of differential morbidity and mortality, in the ®rst 10 years of life, between screen-detected early diagnosed and clinically presenting late diagnosed cohorts of sickle cell disorder patients are also estimated.
Introduction
Sickle cell disorders are serious medical conditions that reduce life expectancy and require lifelong treatment. 1 They mainly affect black, Asian and Mediterranean ethnic minorities in the United Kingdom, and about 10 per cent of births are to women from these high-risk groups.
2 Although such high-risk births are heavily concentrated in major conurbations, they do occur in most districts. 3 The most common and important acute events include painful crises, pneumococcal sepsis, splenic sequestration, acute chest syndrome, stroke and acute anaemia. 4±8 Increasingly, sickle cell disorders are chronic diseases causing, for example, renal failure, chronic lung disease, avascular necrosis of the hip joint and retinopathy, 9±11 and some of the acute conditions have irreversible sequelae involving mental retardation, seizures or deafness. 12 Sickle cell disorders are autosomal recessive haemoglobinopathies, whereby the detection of a signi®cant combination of defective traits in both parents signi®es a one in four risk of the child suffering from the disorder. Antenatal screening for sickle cell disorders can detect defective traits in parents, following which, prenatal diagnosis may be offered as a con®rmatory test for de®nitive foetal diagnosis. The primary objective of antenatal screening is to provide choice over the outcome of an affected pregnancy. 13 Within an antenatal screening programme, the detection of an antenatally diagnosed affected foetus may lead to the termination of the pregnancy. The calculation of a lifetime's use of resources in treating and caring for an affected patient may provide policy-makers with a possible benchmark for their assessment of screening programmes.
Neonatal screening is also available for sickle cell disorders, as the diagnosis of a child with a sickle cell disorder before presentation with symptoms improves the prognosis of affected infants. The early introduction of penicillin prophylaxis and comprehensive care has been shown to reduce mortality and morbidity caused by pneumococcal sepsis and splenic sequestration. 14 The resource consequences of neonatal screening for sickle cell disorders are re¯ected by the difference in lifetime treatment costs between early and late diagnosed individuals with sickle cell disorders. They include potential savings of health service costs as a result of reduced morbidity as well as potential expenditures as a result of improved survival in screen detected patients.
This paper should be read in the context of a programme of research funded by the NHS Health Technology Assessment (HTA) Programme, entitled`Screening for haemoglobinopathies in the United Kingdom: review and economic analysis'. 15 Using, in the main, secondary data sources this programme's aim was to assess the costs and effectiveness of existing and alternative available screening models. Both antenatal and neonatal models were considered, including examination of the impact of antenatal screening on neonatal screening.
The presentation of the full economic evaluation and a comprehensive description of the calculation of lifetime treatment costs are beyond the scope of a single paper. Details of the results of the corresponding economic evaluations of both the antenatal and neonatal screening models will be forthcoming, although the implications of the lifetime treatment costs for the respective economic evaluations are discussed in this paper.
However, the estimates provided in this paper are not restricted to use in conjunction with economic evaluations. The treatment of sickle cell disorders will certainly have ®nancial implications for health authorities in which sickle cell disorders are most common. Indeed, the calculation of the lifetime treatment costs makes explicit the costs incurred by such health authorities. If the costs incurred by health authorities with a high proportion of sickle cell disorder patients are not compensated by reductions in the cost of other disease areas, then they may be justi®ed in claiming extra resources.
Methods
Lifetime treatment costs were estimated separately for sickle cell anaemia and sickle HbC disorder because of their different natural histories and management. 11 Other sickle cell disorders, including sickle HbD disease and sickle b 0 thalassaemia, were assumed to incur similar treatment costs to sickle cell anaemia. 16, 17 The expected consequences of prevention of late diagnoses in both categories of sickle cell disorders, in terms of early deaths averted and severe disability prevented (mental retardation, seizures or deafness), are also presented.
The calculation of the lifetime treatment costs was based on the description of the survival rates of sickle cell disorder patients and the likely events experienced throughout their lifetime. A comprehensive literature review was undertaken, incorporating six medical databases and hand searches of a number of particularly pertinent sources, to estimate the relevant parameters. 15 The baseline assessment of the lifetime treatment costs was based on the best available information on the prognosis of a sickle cell disorder patient born now, and only conventional management of the conditions was considered. Both complications as a result of shortcomings of previous therapy were avoided, and possible future developments in the treatment of sickle cell disorders were not included. The impact of progress in the treatment of sickle cell disorders, such as bone marrow transplantation (BMT), and the increased use of hydroxyurea to control painful episodes were explored in the sensitivity analysis. 18 Lower estimates of the incidence of stroke were also included in the sensitivity analysis, as were alternative costs of an in-patient day. The impact of increased community care was also considered.
A health service perspective was taken for this study, as it was felt that health service costs were most relevant to policymakers. The implications of this approach are raised in the discussion.
Baseline analysis
The estimation of the treatment costs of sickle cell disorder patients born now and managed according to current standards of care comprised a number of elements.
Data on the presentation of sickle cell disorders, in the absence of screening, were obtained from a 1985 study from Jamaica. 19 However, it was felt that diagnosis now would be earlier, so the distribution given by this study was shifted forward 1 year. This meant that 61 per cent of patients present by the end of the ®rst year, 78 per cent by the end of the second year, and 86 per cent by the end of the third year. The remaining 14 per cent present gradually until the age of 10. Similar data for sickle HbC disease were taken from Williams et al., although patients were assumed to present up to the age of 20.
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The incidence rates for pneumococcal sepsis and splenic sequestration are of particular importance as they are the major determinants of deaths averted, and severe disability prevented, as a result of early diagnosis. When a child presents clinically (in the absence of pneumococcal sepsis) treatment with penicillin prophylaxis is initiated, and the anticipated incidence rate for pneumococcal sepsis is reduced. The incidence rates of sepsis for sickle cell disease, with and without prior treatment with penicillin prophylaxis, 21 were combined with the yearly incidence rates for sickle cell anaemia and sickle HbC disease 22 to estimate the`known' and`unknown' diagnosis incidence rates reported in Table 1a and b. Gill et al. followed 694 patients over a 10 year period to establish the incidence rates of splenic sequestration used. 23 The mortality experiences of early and late diagnosed cohorts of patients with sickle cell anaemia and sickle HbC disease were assumed to differ up to the age of 10 years as a result of increased incidence of pneumococcal sepsis 21 and case fatality of splenic sequestration 24, 25 in late diagnosed individuals. Survival of patients with sickle cell disorders can be SCREENING FOR SICKLE CELL DISORDERS expected to vary between sickle cell anaemia and sickle HbC disease 26, 27 as well as between screened and unscreened cohorts. 21 Overall mortality was set to be consistent with current literature, which also informed survival estimates in early and late diagnosed groups after the age of 10 years. 26, 27 The main assumptions underlying the calculation of differential mortality in early and late diagnosed individuals with sickle cell disorders up to the age of 10 years are shown in Table 1a and b.
The age-speci®c frequency of major health service interventions was based on sickle cell disorder-related morbidity and current protocols for diagnosis, routine follow-up and management of complications. Hospital-and community-based services were both considered. Acute complications can occur with different degrees of severity, and chronic organ damage caused by sickle cell disorders can affect almost all organ systems. 28 For the purpose of this study only complications requiring initial hospitalization were considered to incur health service costs.
The incidence rates for the multiple complications associated with sickle cell disorders were considered to re¯ect sickle cell disorder-speci®c events. These studies presented their results in a variety of ways and individuals were recruited at different ages, which made it necessary to derive age-speci®c incidence rates indirectly by estimating age-speci®c years under observation.
Unit costs for the various intervention categories were obtained from a number of sources, including hospital trusts, mainly London based, the published literature, the British National Formulary and the Personal Social Services Research Unit (PSSRU). All costs have been uprated to 1998 values using the NHS pay and prices index.
The costs associated with each of the included acute and chronic events were estimated by describing the interventions involved in the treatment of the respective conditions and then attaching the relevant unit costs to each component. Table 4a and b (see below) describes this process. For each patient year, the proportions of patients experiencing the respective acute and chronic conditions were estimated using the data presented in Table 1a and b. These proportions were then multiplied by the episodic or annual cost of each condition. Summing the costs of treatment for the individual conditions produced an estimate of the annual cost per surviving sickle cell disorder patient for each year. These annual costs were then multiplied by the respective survival rates, and aggregated to estimate the lifetime treatment costs. Costs were included up to the age of 60 years, and were subject to a discount rate of 0 and 6 per cent.
Sensitivity analysis
Treatment of sickle cell disorders is an evolving process, so it was considered necessary to investigate the impact on the cost of treatment of fundamental alternative treatment schedules in the sensitivity analysis. The sensitivity analysis was conducted on a single patient group ± sickle cell anaemia patients who are diagnosed early ± because such disorders are the most severe and increased uptake of screening makes early diagnosis more likely.
For some children who can ®nd a compatible bone marrow donor, BMT can cure sickle cell disorders, although there are associated risks. 29 The main UK centre for BMT in children with sickle cell disorders has estimated that only 17 such operations have been undertaken. The current scope is small, which is mainly due to genetic factors, but also to environmental constraints such as the unpredictable nature of the disease and an immediate mortality rate of around 10 per cent. 30, 31 To test the upper bounds of the use of BMT, it was assumed that 5 per cent of patients could receive such treatment in the future. Cost estimates were obtained from a hospital trust experienced in undertaking BMT. Transplantations are preferably completed by the age of 10 years, and it was assumed that the 5 per cent would be uniformly distributed over the ages of 6±10 years.
In a US trial, hydroxyurea has been shown to reduce the frequency of both painful crises and the incidence of acute chest syndrome. 32 However, no similar trial has been undertaken in the United Kingdom, mainly because of apprehension on the part of patients 33 , although more recently it has been reported that a European register of sickle cell disorder patients treated with hydroxyurea was being set up. 34 It was assumed that the uptake of hydroxyurea may increase in the future and the impact of a 50 per cent uptake across all ages was tested in the sensitivity analysis. The cost of the drug was added, and the rates of painful crises requiring hospitalization and acute chest syndrome were decreased by 58 and 53 per cent, respectively. 32 The cost of treating patients with stroke is high, so that the lifetime treatment cost of sickle cell disorders may be sensitive to assumptions about the prevalence of stroke. The estimates of the incidence of stroke were halved, prompted by recent estimates that were lower than the baseline assessment. The cost of a day in both an intensive care unit and a normal ward were halved and doubled to test the impact of the largest individual cost components.
The ®nal sensitivity analysis explored the possible impact of expanded programmes of community care that can reduce the time spent in hospital for episodes of painful crisis. A beforeand-after study has been completed that implemented a home pain management programme to improve the quality of care and educate sickle cell disorder patients in handling painful crises. 29 The results showed that such programmes can reduce the total number of in-patient days per year associated with painful crises by 32 per cent through a reduction in hospital admissions.
Results
The unit costs of the main components of the interventions used for the monitoring and treatment of sickle cell disorder patients are listed in Tables 2 and 3. SCREENING FOR SICKLE CELL DISORDERS The type and frequency of acute complications are described in Table 4a , and their respective episodic costs reported, as well as the annual costs of any sequelae. Table 4b presents the treatment assumptions made for the chronic conditions associated with sickle cell disorders, as well as the relevant lengths of survival. undiscounted total lifetime treatment costs for a patient with sickle cell anaemia was estimated to either £185 614 (early diagnosis) or £170 026 (late diagnosis), depending on whether the child was diagnosed via a screening programme. The discounted ®gures (6 per cent discount rate) were £53 861 and £51 360, respectively. The respective estimates for patients with sickle HbC disease were £113 739 and £92 323, and £27 848 and £24 917 discounted. The observed differences up to 10 years are illustrative: for sickle cell anaemia patients the extra costs associated with early diagnosis have been reversed by the age of 10, as a result of the prevention of serious sequelae, and late-diagnosed patients have higher cumulative treatment costs. However, the cost of treating early-diagnosed sickle HbC cases remains around £800 higher than for late-diagnosed children by the age of 10. After 60 years, additional treatment costs associated with the prevention of a late diagnosis of sickle cell anaemia have reversed again, because of the lower mortality rate, so that early diagnosed patients require over £15 000 in treatment costs (£2500 discounted). The respective differences for sickle HbC cases are £21 416 and £2931.
The sensitivity analyses, presented in Figure 1 , demonstrate the impact of ®ve alternative scenarios. Doubling the cost of inpatient bed days has the largest effect, moving the undiscounted lifetime treatment costs to over £231 000 (discounted £53 860), a 25 per cent (34 per cent) increase. All the other assumptions reduced the lifetime costs. Increased use of BMT would reduce the undiscounted lifetime treatment cost by 12 per cent (5 per cent undiscounted), whereas a 50 per cent reduction in the incidence of stroke cuts undiscounted treatment costs by 11 per cent (£165 680), and discounted costs by 9 per cent (£49 010). Increased uptake of hydroxyurea to control painful crises reduced undiscounted costs considerably, by 17 per cent (£153 470), although discounted costs fell by only 1 per cent (£53 540). However, it must be borne in mind that the use of BMT and hydroxyurea, and reduced stroke incidence also improve overall morbidity and mortality rates.
Implementing the community-based model of caring for patients experiencing painful crises, assuming a 32 per cent reduction in the number of in-patient days, resulted in a reduction in the discounted and undiscounted lifetime treatment costs of 8 per cent (£49 363 and £170 496, respectively). The largest decrease in the lifetime costs arises when the cost of an in-patient bed day was halved, resulting in an undiscounted cost of £132 820 (£37 470 undiscounted), a reduction of over 28 per cent (30 per cent).
The process of calculating the differential treatment costs for early and late diagnosed sickle cell disorder patients produced additional data describing the morbidity and mortality avoided through early diagnosis. The results are presented in Table 6 . Early deaths averted are de®ned as the difference in the mortality rate, between the screened and unscreened cohorts, up to the age of 10. For sickle cell anaemia and sickle HbC disease, it was found that 1.25 and 0.57, respectively, early deaths were averted for every 100 early-diagnosed children. This means that a screening programme, to prevent one early death, must diagnose 80 sickle cell anaemia cases; the equivalent ®gure for sickle HbC cases is 175. Early diagnosis also reduces the frequency of serious disability, as a result of the reduction in the incidence pneumoccocal sepsis. It was estimated that for sickle cell anaemia and sickle HbC disease, respectively, 1.6 and 0.4 cases of severe disability would be avoided every 1000 early diagnoses. Thus, a screening programme, to prevent one early death, must diagnose 625 sickle cell anaemia cases; the equivalent ®gure for sickle HbC cases is 2500.
Discussion
The resource usage presents a best estimate given the available state of knowledge. There remains considerable uncertainty, however, about the survival of cohorts of patients with sickle cell disorders who are currently born and the possible development of new complications or new interventions. The method adopted in this study allows parameters, in particular resource use and cost parameters, to be varied according to local conditions, as well as facilitating the inclusion of new interventions, and their associated impact on survival and complications.
The baseline results show that sickle cell anaemia in particular is currently an expensive condition to treat, although it appears to be signi®cantly less costly than other haemoglobinopathies, such as b thalassaemia major. 35 The annual number of pregnancies affected with sickle cell disorders in the United Kingdom has recently been put at around 170, with sickle cell anaemia accounting for 74 per cent of cases, and sickle HbC disease for 26 per cent. 15 Thus, a maximum estimate of the cost to the NHS of treating sickle cell disorders in any given year would be 170 multiplied by the undiscounted total lifetime treatment costs, or £28.37 million.
The geographical distribution of cases of sickle cell disorders around the United Kingdom is highly skewed, with the majority of districts experiencing a single case only very rarely. Indeed, only eight districts in the United Kingdom have been found to have a foetal sickle cell disorder prevalence of over 10 per 10 000 pregnancies. 15 If these districts can prove that the incursion of costs associated with the treatment of sickle cell disorders is not balanced by a reduction in the costs of treating other expensive conditions they may justi®ably argue for additional funding.
Sensitivity analyses were used to explore the impact of some alternative treatment and cost assumptions; they suggested that most developments will not have a major impact on the lifetime treatment costs, although the increased uptake of hydroxyurea could be a signi®cant factor.
The estimates of lifetime treatment costs derived in this paper are intended to serve as indicators for the approximate magnitude of expenditure in treating patients with sickle cell disorders. Although the estimated survival rates show a large proportion of patients surviving to 60 years, especially of sickle HbC disease, it was felt that any survival assumptions made beyond that age would be suf®ciently uncertain to justify 60 years as a cut-off point for the inclusion of treatment costs. Moreover, discounting the annual costs minimizes the impact of excluding costs incurred past 60 years.
The costs used in the study were chosen, as far as possible, to represent the costs faced by decision-makers within the UK NHS. Although the cost estimates were obtained from a variety of sources, the majority of costs were estimated in conjunction with hospital ®nance departments. Drug costs were taken from the British National Formulary, which may tend to overestimate the unit costs paid by hospitals, which may negotiate some reductions in price.
The only costs obtained from the literature referred to the long-term costs of caring for patients with chronic sequelae. The costs of treating stroke patients were taken from a 508 JOURNAL OF PUBLIC HEALTH MEDICINE UK-based paper, 62 although the costs of treatment of sepsis sequelae were available only from a US-based paper. 12 More detailed analysis of such costs was beyond the resources of the current study, but it was felt that the published estimates were suitably rigorous for inclusion in the study. Moreover, the impact of the cost of stroke was analysed by looking at the effect of halving the incidence rate of stroke in the sickle population.
The estimates are likely to present minimum values, as only major health service interventions have been included. It is recognized that non-health care expenditure, related to sickle cell disorders, will also be required during the course of a lifetime. The accuracy of the results should not be affected signi®cantly, as a US study has found that 90 per cent of medical costs for sickle cell disorder patients resulted from hospitalization. 37 The possible impact of community-based models of care for patients with sickle cell disorders was explored in the sensitivity analysis. Treating and educating patients experiencing painful crises in the home was found to reduce the total lifetime treatment costs, although the overall impact on costs was not huge. However, the increased ability to care for themselves could also positively affect patients' quality of life, so such programmes could bene®t all concerned.
It was recognized that recent guidelines for economic evaluation have recommended that resource use be identi®ed and valued from the societal perspective, 38 thus requiring the inclusion of such non-health care resources as child care and transportation, as well as some form of measurement of the effects of lost productivity. The estimation of the non-health care resources required by patients with sickle cell disorders would be an interesting exercise, as would the prediction of the employment pathways of sickle cell disorder patients. However, it was felt that the complexities and uncertainties inherent in such an exercise would dwarf those imposed in the estimation of the lifetime treatment costs. It was also felt that policy-makers would be most likely to include health care costs alone in their allocation decisions.
The calculation of differential morbidity and early mortality rates between early diagnosed (screened) and late diagnosed (unscreened) cohorts was based on the differential survival presented in Table 5a and b, which includes assumptions that all children identi®ed by a screening programme with sickle cell disorder were given appropriate care, and that patients had a compliance to prophylactic penicillin therapy similar to that achieved by Gaston et al. 21 Both assumptions are conservative 39, 40 and likely to exaggerate the number of early deaths averted as a result of the early management of the disease.
Gessner et al. have previously calculated the number of deaths averted as a result of screen detection as 2.44 per 100 cases. 12 The difference between their estimate and the estimate of 1.25 presented here is due to assumptions made regarding the presentation of non-screen detected patients with sickle cell disease. Gessner et al. have assumed that all non-screen detected patients present at exactly 1.75 years, whereas the data used in this paper re¯ect an assumption of earlier presentation with symptoms. The potential of screening to avert deaths is increased in locations where non-screened patients present later, because there is a greater risk reduction in the incidence of serious illness.
Cross-sectional analyses of the costs associated with sickle cell disorders have been published, 37, 41 as have the lifetime treatment costs of other disease areas. 42 The calculation of the lifetime treatment costs of sickle cell disorders provides health authorities with information regarding the likely burden on resources of sickle cell disorder patients over the course of their lifetime. This information may be used at a local level, in conjunction with information on the age-speci®c prevalence of sickle cell disorders in the area, to ensure that an adequate capacity of resources is available. The details provided in this paper could then be used at the disaggregated level of the categories of interventions.
Alternatively, lifetime treatment costs should also be of interest to those involved in the provision of screening programmes, antenatally and neonatally, as well as to policymakers interested in increasing the information base on which policy is decided. Screening for sickle cell disorders alters the level of resources used in two, opposite, directions. First, both antenatal and neonatal screening improve the prognosis of an affected baby through early diagnosis, preventing morbidity and mortality, with the subsequent effect that the treatment costs of early diagnosed patients are, on average, more than those of their late diagnosed counterparts. Secondly, antenatal screening saves the full lifetime treatment costs whenever an affected pregnancy is terminated. Such calculation of lifetime costs for sickle cell disorders may be used to aid policy-makers with respect to the provision of antenatal and neonatal screening programmes.
